Relypsa, Inc. RLYP saw a big move in the last trading session, as the company's shares fell by over 7% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. This continues the recent trend of the company, as the stock is now trading within the volatile price range of $21.39 to $25.41 in the past one-month time frame.
Although this slump was obviously disappointing, the company, a pharmaceutical firm specializing in non-absorbed polymeric drugs, has seen 1 positive revisions and its current year earnings consensus has moved higher over the past few weeks. This suggests that the recent slump might be a temporary blip on the radar for RLYP. So make sure to keep an eye on this stock going forward to see if yesterday's price decline is confirmed by more weakness, or if it can rebound in the weeks ahead.
RLYP currently holds a Zacks Rank #3 (Hold) while its Earnings ESP is positive.
Investors interested in the Medical- Generic Drugs industry may consider better-ranked stocks like Akorn, Inc. AKRX, Mallinckrodt plc MNK and KaloBios Pharmaceuticals, Inc. KBIO. While Akorn and Mallinckrodt hold a Zacks Rank #1 (Strong Buy), KaloBios carries a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
RELYPSA INC RLYP: Free Stock Analysis Report
AKORN INC AKRX: Free Stock Analysis Report
MALLINCKRODT PL MNK: Free Stock Analysis Report
KALOBIOS PHARMA KBIO: Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
